TY - JOUR
T1 - Prudent Precaution in Clinical Trials of Nanomedicines
AU - Marchant, Gary
AU - Lindor, Rachel A.
PY - 2012/12
Y1 - 2012/12
N2 - Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.
AB - Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.
UR - http://www.scopus.com/inward/record.url?scp=84872167408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872167408&partnerID=8YFLogxK
U2 - 10.1111/j.1748-720X.2012.00711.x
DO - 10.1111/j.1748-720X.2012.00711.x
M3 - Article
C2 - 23289685
AN - SCOPUS:84872167408
SN - 1073-1105
VL - 40
SP - 831
EP - 840
JO - Journal of Law, Medicine and Ethics
JF - Journal of Law, Medicine and Ethics
IS - 4
ER -